CASI net loss narrows to USD 20 million in H1 FY26; revenue falls 5.8% to USD 9.8 millionPUBT·Aug 14 at 10:45 AMCASIF0.00%
CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results | CASIF Stock NewsStockTitan·Aug 14 at 02:45 AMCASIF0.00%
CASI wins HKIAC arbitration award topping RMB 100 million against JuventasPUBT·Jul 15 at 10:31 AMCASIF0.00%
CASI doses first patient in Phase 1/2 CID-103 trial for renal allograft antibody-mediated rejection in ChinaPUBT·Jul 1 at 12:17 PMCASIF0.00%
CASI Pharmaceuticals settles Evomela China license arbitration with AcrotechPUBT·Jun 29 at 10:30 AMCASIF0.00%
